Abstract
We have investigated c-erbB-2 protein expression in a large cohort of well-characterized colorectal tumours, and in a subset of lymph node metastases. We have also evaluated a Val(655)lle single nucleotide polymorphism, which is associated with an increased risk of breast cancer, in a subset of the colorectal cancer patients and in healthy control subjects. Immunohistochemical studies revealed that while 81.8% of tumours expressed c-erbB-2, in the majority of cases equivalent levels of c-erb-B2 were seen in adjacent normal mucosa. Colon tumours were significantly more likely to express c-erbB-2 than rectal tumours (P=0.015). Only 52.4% of the metastases displayed staining patterns concordant with their primary tumour, indicating that determination of c-erbB-2 protein in colorectal tumours cannot predict the status of lymph node metastases, PCR-RFLP analysis of the Val(655)lle single nucleotide polymorphism demonstrated that allele Frequencies were identical between colorectal cancer patients and a control group of Caucasian subjects (lle=0.80 and Val=0.20 in each case), indicating that it is not related to the risk of developing colorectal cancer in this population. Furthermore, there was no relationship between c-erbB-2 protein expression and gene polymorphism (P=0.58). In terms of prognosis, no association was seen between either c-erbB-2 protein expression or the presence of the Val allele and patient survival (P > 0.05 in each case), suggesting that c-erbB-2 is not a prognostic marker in colorectal cancer. (C) 2002 Cancer Research UK.
| Original language | English |
|---|---|
| Pages (from-to) | 568-573 |
| Number of pages | 5 |
| Journal | British Journal of Cancer |
| Volume | 86 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2002 |
Keywords
- colorectal cancer
- c-erbB-2
- immunohistochemistry
- PCR-RFLP
- polymorphism
- prognosis
- HER2 GENETIC-POLYMORPHISM
- BREAST-CANCER
- PROGNOSTIC-SIGNIFICANCE
- EXPRESSION
- HER-2/NEU
- SURVIVAL
- PROTEIN
- ADENOCARCINOMA
- AMPLIFICATION
- ONCOPROTEIN
Cite this
c-erbB-2 is not a major factor in the development of colorectal cancer. / McKay, J. A.; Loane, Joseph; Ameyaw, M. M.; McLeod, H. L.; Ross, V. G.; Murray, Graeme Ian; Cassidy, J.
In: British Journal of Cancer, Vol. 86, No. 4, 2002, p. 568-573.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - c-erbB-2 is not a major factor in the development of colorectal cancer
AU - McKay, J. A.
AU - Loane, Joseph
AU - Ameyaw, M. M.
AU - McLeod, H. L.
AU - Ross, V. G.
AU - Murray, Graeme Ian
AU - Cassidy, J.
PY - 2002
Y1 - 2002
N2 - We have investigated c-erbB-2 protein expression in a large cohort of well-characterized colorectal tumours, and in a subset of lymph node metastases. We have also evaluated a Val(655)lle single nucleotide polymorphism, which is associated with an increased risk of breast cancer, in a subset of the colorectal cancer patients and in healthy control subjects. Immunohistochemical studies revealed that while 81.8% of tumours expressed c-erbB-2, in the majority of cases equivalent levels of c-erb-B2 were seen in adjacent normal mucosa. Colon tumours were significantly more likely to express c-erbB-2 than rectal tumours (P=0.015). Only 52.4% of the metastases displayed staining patterns concordant with their primary tumour, indicating that determination of c-erbB-2 protein in colorectal tumours cannot predict the status of lymph node metastases, PCR-RFLP analysis of the Val(655)lle single nucleotide polymorphism demonstrated that allele Frequencies were identical between colorectal cancer patients and a control group of Caucasian subjects (lle=0.80 and Val=0.20 in each case), indicating that it is not related to the risk of developing colorectal cancer in this population. Furthermore, there was no relationship between c-erbB-2 protein expression and gene polymorphism (P=0.58). In terms of prognosis, no association was seen between either c-erbB-2 protein expression or the presence of the Val allele and patient survival (P > 0.05 in each case), suggesting that c-erbB-2 is not a prognostic marker in colorectal cancer. (C) 2002 Cancer Research UK.
AB - We have investigated c-erbB-2 protein expression in a large cohort of well-characterized colorectal tumours, and in a subset of lymph node metastases. We have also evaluated a Val(655)lle single nucleotide polymorphism, which is associated with an increased risk of breast cancer, in a subset of the colorectal cancer patients and in healthy control subjects. Immunohistochemical studies revealed that while 81.8% of tumours expressed c-erbB-2, in the majority of cases equivalent levels of c-erb-B2 were seen in adjacent normal mucosa. Colon tumours were significantly more likely to express c-erbB-2 than rectal tumours (P=0.015). Only 52.4% of the metastases displayed staining patterns concordant with their primary tumour, indicating that determination of c-erbB-2 protein in colorectal tumours cannot predict the status of lymph node metastases, PCR-RFLP analysis of the Val(655)lle single nucleotide polymorphism demonstrated that allele Frequencies were identical between colorectal cancer patients and a control group of Caucasian subjects (lle=0.80 and Val=0.20 in each case), indicating that it is not related to the risk of developing colorectal cancer in this population. Furthermore, there was no relationship between c-erbB-2 protein expression and gene polymorphism (P=0.58). In terms of prognosis, no association was seen between either c-erbB-2 protein expression or the presence of the Val allele and patient survival (P > 0.05 in each case), suggesting that c-erbB-2 is not a prognostic marker in colorectal cancer. (C) 2002 Cancer Research UK.
KW - colorectal cancer
KW - c-erbB-2
KW - immunohistochemistry
KW - PCR-RFLP
KW - polymorphism
KW - prognosis
KW - HER2 GENETIC-POLYMORPHISM
KW - BREAST-CANCER
KW - PROGNOSTIC-SIGNIFICANCE
KW - EXPRESSION
KW - HER-2/NEU
KW - SURVIVAL
KW - PROTEIN
KW - ADENOCARCINOMA
KW - AMPLIFICATION
KW - ONCOPROTEIN
U2 - 10.1038/sj.bjc.6600127
DO - 10.1038/sj.bjc.6600127
M3 - Article
VL - 86
SP - 568
EP - 573
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
IS - 4
ER -